BCL2 and plasma cell myeloma: Overexpression of Bcl-2 has been shown to inhibit apoptosis of plasma cells (93), and Bcl-2 inhibitors have demonstrated efficacy in the treatment of certain tumor diseases characterized by over proliferation of plasma cells, such as multiple myeloma (94) (Figure 1).